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Baseline staging of melanoma with unknown primary site: the
value of serum s100 protein and positron emission tomography
Abstract
BACKGROUND: Baseline staging is important in all melanoma types, including melanoma with
unknown primary site (MUP). Staging includes different examination strategies, each with different
accuracy. OBJECTIVE: To determine the value of serum S100 protein levels and positron emission
tomography (PET) in the baseline staging of MUP. METHODS: Twenty patients with MUP were
evaluable for the analysis between 1996 and 2007 with both S100 assessment and PET performed for
baseline staging. RESULTS: Serum S100 was elevated in 7 patients (35%). The PET scan detected the
metastases in 6 of 7 patients with elevated serum S100 protein showing a strong correlation (p = 0.005).
Patients with metastases had significantly higher serum S100 levels (p = 0.01) than the ones without.
Serum S100 protein was shown to be discriminative between patients with and without metastases
(receiver-operating characteristic, p = 0.012) with 75% sensitivity and 92% specificity. CONCLUSION:
Serum S100 protein appears to be a sensitive as well as specific marker to detect metastases. We
therefore might recommend serum S100 assessment to be included in the baseline staging of MUP.
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 Introduction 
 Melanoma may present as metastatic tumor without 
an identifiable primary lesion, as so-called melanoma 
with unknown primary site (MUP), first described in 
1952  [1] . Diagnostic criteria for MUP were initially pro-
posed in 1963 by Dasgupta et al.  [2] . Current diagnostic 
criteria for MUP include (1) histological confirmation of 
metastatic melanoma, (2) the absence of a previous cuta-
neous tumor, pigmented or not, excised or otherwise re-
moved without histological examination, and (3) the ex-
clusion of melanoma in urogenital, otolaryngological or 
ophthalmological sites  [3] . Various reports suggest that 
approximately 1–8% of all melanomas present as MUP  [3, 
4] . These patients can be categorized into two groups: 
those who present with metastases in a localized region 
(43% of all MUP cases) and those with multiple sites of 
presentation (57% of all MUP cases)  [4] .
 S100 protein is a 21-kDa calcium-binding acidic pro-
tein, which is expressed in cells of neural origin (   -di-
mer), including melanocytes (   -dimer)  [5] . Given that 
available assays detect the   -subunit, both    - and    -
forms are detected. S100 serum levels are known to be 
elevated in patients with disseminated melanoma  [6–9] . 
Elevation in serum S100 protein levels appears to be the 
first sign of melanoma progression and thus enables an 
earlier detection of distant metastases  [10–14] . Further-
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more, measuring S100 protein is useful in monitoring 
success of chemotherapy in stage IV disease  [15, 16] . 
However, the significance of serum S100 protein detec-
tion in the diagnosis of MUP has not been specifically 
investigated.
 Positron emission tomography (PET) is widely used in 
oncology for lesion detection and characterization as well 
as for accurate lesion localization  [17] . The importance of 
PET in melanoma staging has been extensively studied 
and its usefulness confirmed  [18–20] . Melanoma cells usu-
ally demonstrate a high uptake of the glucose analog  18 F-
fluorodeoxyglucose (FDG), which was the finding that set 
the rationale for the use of FDG in melanoma  [21, 22] .
 The aim of this study was to determine the value of 
serum S100 measurement and PET in the baseline stag-
ing of patients with MUP.
 Patients and Methods 
 Patients 
 We retrospectively reviewed the medical histories of melano-
ma patients with MUP diagnosed between 1996 and 2007 at our 
Department. The dates corresponding to S100 evaluation and 
PET together with respective findings were collected. All patients 
were assessed according to the guidelines of the Swiss Cancer 
League for stage III or high-risk melanoma  [23] . The assessment 
was performed as follows: complete examination of the skin in-
cluding dermoscopy (if available, with computer-assisted sys-
tems) of atypical moles, palpation of all lymph node regions and 
the abdomen, a partial- (without lower legs’ scan) or full-body 
(with lower legs’ scan) PET scan and the assessment of the serum 
S100 level. We did not perform any additional examinations to 
specifically seek for tumors in urogenital, otolaryngological or 
ophthalmological (noncutaneous) sites. Patient details are shown 
in  table 1 .
 S100 Protein ELISA 
 Serum S100 levels were measured by an enzyme immunoassay 
at the Department of Clinical Immunology, University Hospital 
Zurich. The two-site, one-step Sangtec 100 ELISA was used
(DiaSorin, Saluggia, Italy; obtained from Sodiac SA, Losone, 
Switzerland). Serum S100 protein was considered normal for val-
ues  ! 0.2   g/l.
 Positron Emission Tomography 
 PET scans were performed at the Department of Nuclear Med-
icine, University Hospital Zurich. PET studies were performed on 
a GE Advance PET scanner (GE Medical Systems, Waukesha, 
Wisc., USA), which acquires 35 two-dimensional sections of 4.25 
mm thickness per increment with an axial field of view of 14.6 cm 
and a maximum of 13 consecutive cradle positions. After fasting 
for at least 4 h, the patients were injected 300–400 MBq of FDG 
intravenously 45–60 min before scanning. PET studies were per-
formed in a partial-body or whole-body mode. Attenuation cor-
rection was performed using the built-in rotating  68 Ge sources. 
To improve the image quality and to reduce the computation, a 
multiplicative iterative reconstruction algorithm for improve-
ment of time was employed.
 Statistical Analysis 
 Statistical analysis was performed with the SPSS software 
package, version 12.0 (SPSS, Chicago, Ill., USA). Receiver-operat-
ing characteristic (ROC) curves were used to evaluate the dis-
criminative strength of S100 protein to differentiate between pa-
tients with and without metastases as seen by PET. p values of less 
than 0.05 were considered statistically significant. Box plots and 
ROC curve graphs were generated using SPSS.
 Results 
 The average interval between PET and S100 evalua-
tion was 10 days (range 0–41 days). Twenty patients were 
evaluable for the analysis. Serum S100 was elevated in 7 
out of 20 patients (35%) at the time of diagnosis. There 
were no differences in S100 levels with respect to different 
tumor stages (data not shown). Patients with metastases 
visualized by PET had significantly higher serum S100 
levels as compared to the ones without (Mann-Whitney 
U test, p = 0.01), as shown in  figure 1 a. Interestingly, 3 out 
of 7 patients with elevated S100 levels had symptoms (e.g. 
pain) or findings in the clinical examination suggestive 
of a tumor, while 4 patients were completely asymptom-
atic.
 The PET scan detected metastases in 6 out of 7 patients 
with elevated S100 values showing a strong correlation 
between PET positivity and elevated S100 protein (Spear-
man’s   = 0.606, p = 0.005). Furthermore, serum S100 
could be shown to have a discriminative value between 
patients with and without metastases (ROC, p = 0.012; 
 fig. 1 b). Serum S100 levels were indicative of metastases 
Table 1. Patient characteristics
Gender
Male 16
Female 4
Site of first metastasis
Skin and subcutaneous 5
Lymph node 11
Organs and bones 4
PET/CT
Partial-body 9
Whole-body 10
Not assessed 1
Age at first diagnosis, years
Median 51.69
Range 24–80
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with 75% sensitivity and 92% specificity. Furthermore, 
measurement of S100 had a positive predictive value of 
78% (to detect the presence of metastases when S100 was 
 6 0.2   g/l) and a negative predictive value of 100% (to 
exclude the presence of metastases when S100 was  ! 0.2 
  g/l).
 During the subsequent follow-up, 7 out of 11 patients, 
who initially had normal S100 levels, demonstrated a 
pathological increase in serum S100, indicating progres-
sion of the disease. The median time between first diag-
nosis of MUP and the first elevated S100 value was 529 
days (range 120–1,911 days). At this time point, 6 out of 
these 7 patients had imaging-confirmed metastatic dis-
ease. The last patient had an unspecific, non-metastasis-
associated S100 elevation (0.3   g/l).
 Conclusions 
 Our current study shows that the use of S100 protein 
in conjunction with PET is useful in the baseline staging 
of MUP. Early detection of metastases in melanoma pa-
tients, including the ones with MUP, is important to es-
tablish an adequate treatment scheme as early as possible. 
To our knowledge, no standardized international guide-
lines for staging procedures and follow-up are currently 
available for MUP. Recommendations for baseline stag-
ing for patients with metastatic MUP include chest X-ray/
computer tomography (CT), abdominal ultrasound/CT 
and ultrasound of the regional lymph nodes and brain 
CT/magnetic resonance imaging  [24] . At the University 
Hospital of Zurich, where our Department is located, 
staging and follow-up of MUP are performed according 
to the guidelines of the Swiss Cancer League (Skin Can-
cer Group) as for stage III or high-risk melanoma patients 
with tumor thickness  1 4 mm  [23] . Those patients are ini-
tially assessed using PET and measurement of serum 
S100, which is then followed by S100 measurement with 
either ultrasound examination of lymph nodes + chest 
X-ray or PET every 6 months together with clinical as-
sessment every 3 months for the first 3 years. Afterwards, 
ultrasound and S100 assessment or PET or CT scan as 
well as clinical checks are performed twice a year for 2 
years. Five years after the initial diagnosis, annual clini-
cal follow-ups with monitoring serum S100 levels are rec-
ommended.
 S100 protein is a well-established marker for the detec-
tion of new melanoma metastases  [13] . Elevation of S100 
protein may even present as a first sign of the progressing 
disease  [10] . False-negative results may occur, however, 
especially in MUP patients and in those with amelanotic 
melanoma metastases. False-positive findings, on the 
other hand, are associated with the damage of the central 
nervous system and increased sun exposure (ultraviolet 
radiation)  [25] . Nevertheless, S100 protein was shown to 
be more frequently positive in cases with MUP than mel-
anoma antigen E1, another marker employed in the diag-
nosis of melanoma  [26] . Our results demonstrate an un-
expectedly higher sensitivity and specificity of S100 mea-
surement in our study group than in previous reports, 
where sensitivity ranged between 30 and 60% and speci-
ficity between 93 and 100% depending on the disease 
stage  [27, 28] . In contrast to other studies, we performed 
analysis on a rather homogenous collective of patients 
with MUP, which is probably the reason for the observed 
high sensitivity and specificity of S100 protein to detect 
metastases.
 Recently, Strobel et al.  [29] have shown that PET ac-
curately identifies lymph node or distant metastases in 
melanoma patients with elevated serum S100 levels. Our 
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 Fig. 1. a Serum S100 levels in patients with 
MUP.  Results  are grouped by the pres-
ence/absence of metastases detectable by 
PET displaying median (bar), quartile 
range (box), minimum/maximum (whis-
kers) and outliers (circles, values 1.5–3
box lengths from ends). The significant 
difference is indicated and the p value 
shown.  b Discriminative value of serum 
S100 protein to detect metastases assessed 
by ROC curve statistics. 
 Oberholzer /Urosevic /Steinert /Dummer 
 
Dermatology 2008;217:351–355354
results support these general findings in the special clin-
ical situation of MUP. On the other hand, various other 
imaging procedures such as ultrasound mapping of 
lymph nodes, chest X-ray and CT are used for the early 
detection of progressive disease. For lung metastasis (es-
pecially pulmonary lymphatic carcinomatosis) and brain 
metastases, high-resolution CT and magnetic resonance 
imaging may be more accurate. Although high-resolu-
tion CT is the diagnostic modality of choice, Acikgoz et 
al.  [30] suggested that the recognition of various PET pat-
terns may also allow an accurate diagnosis of melanoma 
lung metastases. However, in detecting brain metastases 
of melanoma, magnetic resonance imaging is still more 
sensitive than fusion PET-CT  [31] . These imaging tech-
niques are however rather expensive. Facey et al.  [32] have 
recently shown for the UK that PET scans are used incon-
sistently in cancer patients throughout the country and 
that costs vary from 635 to 1,300 GBP per scan. Further 
studies are required to show the impact of FDG-PET on 
patient management or the added value in the diagnostic 
pathway. Furthermore, these imaging techniques may 
unnecessarily expose patients to ionizing radiation and 
are not directly associated with tumor biology as S100 
(tumor marker) and PET (metabolic activity of the tumor 
cells). The importance of additional examinations to 
identify primary melanoma of less frequent origin in the 
presence of overt metastatic disease (i.e. urogenital, oto-
laryngological or ophthalmological sites) remains un-
clear. We therefore suggest a broad assessment of serum 
S100 levels in the clinics in patients suspected of having 
MUP to allow data collection on a larger group of pa-
tients. If serum S100 levels turn out to be reliable in pre-
dicting the presence of metastases in MUP, this marker 
can be used in the future as an indicator for further PET 
assessment.
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